Search for dissertations about: "Gunilla Enblad"

Showing result 1 - 5 of 26 swedish dissertations containing the words Gunilla Enblad.

  2. 1. Hodgkin's disease in young and elderly patients : clinical and pathological studies

    Author : Gunilla Enblad; Uppsala universitet; []
    Keywords : MEDICINE; MEDICIN;

    Abstract : .... READ MORE

  4. 2. Prognostic signficance of tumor cell markers in diffuse large B-cell lymphoma with special emphasis on lymphoma localization

    Author : Maysaa Abdulla; Rose-Marie Amini; Gunilla Enblad; Wolfram Klapper; Uppsala universitet; []
    Keywords : ;

    Abstract : Diffuse large B-cell lymphoma (DLBCL) is the most common type of high-grade B-cell lymphoma with different clinical, morphological, immunophenotypical, and molecular features. DLBCL is curable in 60-70% of patients when treated with standard immunochemotherapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). READ MORE

  5. 3. Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

    Author : Amal Abu Sabaa; Gunilla Enblad; Peter de Nully Brown; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; DLBCL; R-CHOP; EFS24; PEA; Biomarker; ELISA; TCL1A.;

    Abstract : The general aim of this thesis was to study the prognostic clinical and biological markers of Diffuse Large B-cell Lymphoma (DLBCL).Paper I: Utilizing population-based data for patients with DLBCL in Sweden, the study aimed to establish whether event free survival at 24 months (EFS24) was a reproducible milestone. READ MORE

  6. 4. Aggressive B-cell Lymphomas : Studies of Treatment, FDG-PET Evaluation and Prognostic Factors

    Author : Magdalena Adde; Gunilla Enblad; Hans Hagberg; Anna Laurell; Tor Ekman; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; Onkologi; Oncology; Onkologi;

    Abstract : To improve outcome in young, high-risk lymphoma patients, treatment was intensified, adding etoposide and rituximab to standard CHOP treatment. Granulocyte-colony stimulating factor (G-CSF) enabled treatment bi-weekly. Results were promising: overall (OS) and event-free survival (EFS) 79% and 60% respectively, median follow up 27 months. READ MORE

  7. 5. Long-term side effects after treatment of Hodgkin's lymphoma

    Author : Anne Andersson; Beatrice Melin; Ulf Näslund; Gunilla Enblad; Harald Holte; Umeå universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Hodgkin; survivorship; long-term side effects; cardiovascular disease; second malignancy; infections; prevention; Oncology; Onkologi; onkologi; Oncology;

    Abstract : Background Long-term side effects associated with the treatment of Hodgkin’s lymphoma (HL) have frequently been reported during the last decades. Studies have shown increased mortality in HL survivors. READ MORE